ArticleWorld journal of surgery2007
Chronic viral hepatitis and hepatocellular carcinoma.
Article in World journal of surgery, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 98 citations in OpenAlex.
- Effect of mosapride citrate on gastric emptying in interferon-induced gastroparesis.Digestive diseases and sciences · 2012Trial
- Comparison of inpatient outcomes in patients with Hepatitis B, Hepatitis C, and Hepatitis B and C co-infection with Cirrhosis.Irish journal of medical science · 2024Article
- Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy.Frontiers in pharmacology · 2022Article
- Hepatocellular Carcinoma in Oman: An analysis of 284 cases.Sultan Qaboos University medical journal · 2020Article
- Hepatic Stellate Cells and Hepatocarcinogenesis.Frontiers in cell and developmental biology · 2020Review
- A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015.Drug design, development and therapy · 2019Article
- Hepatitis C Infection and Periodontal Disease: Is there a Common Immunological Link?Journal of immunology research · 2018Review
- Predictors and Barriers to Hepatitis B Screening in a Midwest Suburban Asian Population.Journal of community health · 2017Article
- Targeting blockage of STAT3 inhibits hepatitis B virus-related hepatocellular carcinoma.Cancer biology & therapy · 2016Review
- Evaluation of total hepatocellular cancer lifespan, including both clinically evident and preclinical development, using combined network phenotyping strategy and fisher information analysis.Seminars in oncology · 2015Article
- Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma.Journal of radiation research · 2015Article
- Aberrant DNA methylation in hepatocellular carcinoma tumor suppression (Review).Oncology letters · 2014Article
- Treatment of spontaneous ruptured hepatocellular carcinoma: A single-center study.Pakistan journal of medical sciences · 2014Article
- Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection.Clinical and experimental immunology · 2014Article
- Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma.International journal of clinical and experimental pathology · 2014Article
- Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2013Article
- Oridonin induces the apoptosis of metastatic hepatocellular carcinoma cells via a mitochondrial pathway.Oncology letters · 2013Article
- Primary pleomorphic liposarcoma of liver: a case report and review of the literature.Case reports in hepatology · 2013Article
- Tumor factors associated with clinical outcomes in patients with hepatitis B virus infection and hepatocellular carcinoma.Gastroenterology & hepatology · 2012Article
- Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is the third leading cause of death from malignancy worldwide, and its increasing incidence parallels rising global rates of hepatitis B (HBV) and hepatitis C (HCV).
methodsThis retrospective review was undertaken to identify differences in the epidemiology and tumor characteristics of 255 patients with HCC due to chronic HBV (n = 105) or HCV (n = 150).
resultsHepatitis B patients were predominantly Asian (84%), whereas HCV patients were predominantly Caucasian (72%; p < 0.0001). Hepatitis B patients exhibited stronger family histories of liver disease (54%) and HCC (33%), whereas HCV risk factors included blood transfusion (56%), intravenous drug abuse (31%), and alcohol consumption (44%; p < 0.0001 for all comparisons). Pretreatment laboratory values showed lower albumin and platelet levels but higher bilirubin and AST levels in HCV versus HBV patients (p < 0.0001 to 0.01). As cirrhosis was present in nearly all HCV patients, but only in 79% of HBV patients, HCV patients had more stigmata of portal hypertension, including ascites (65%), varices (86%), splenomegaly (77%), and encephalopathy (41%; p < 0.0002 for all comparisons). Although tumors in HBV patients were larger (7.3 cm versus 5.1 cm; p = 0.0001) and more frequently bilobar, the tumor grade, number of tumors, and metastases were similar for both groups. Hepatitis C patients received less treatment, including chemoembolization and surgical resection. The 5-year survival was higher in HBV patients compared to HCV patients (56% versus 36%, p = 0.046).
conclusionsPatients with HBV- and HCV-related HCC have different epidemiologic, clinical, and survival characteristics. More HCV patients presented with advanced cirrhosis, received less aggressive treatment, and experienced lower 5-year survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.